Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway
Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway
复制标题
齐墩果酸通过 PI3K/Akt 通路抑制体内外前列腺癌细胞的存活和增殖
DOI：
10.1007/s13277-015-4655-9
复制
发表时间：
2016-06-01
期刊：
影响因子：
--
通讯作者：
Xing, Yifei
中科院分区：
文献类型：
--
作者：
Li, Xuechao;Song, Yarong;Xing, Yifei
齐墩果酸 (OA) 是一种天然存在的五环三萜类化合物，具有多种药理活性，包括已在多种人类癌症中得到证实的抗癌作用。然而，天然 OA 对人类前列腺癌的潜在影响仍不清楚。本研究旨在探讨 OA 是否以及如何在前列腺癌中发挥抗癌作用。我们的数据显示，OA 以剂量依赖性方式抑制前列腺癌 PC-3、DU145 和 LNCaP 细胞中的细胞活力和增殖，并促进细胞凋亡和 G(0)/G(1) 期细胞周期停滞。此外，OA还可以剂量依赖性地调节凋亡相关蛋白和细胞周期相关蛋白的表达水平以及PI3K/Akt通路的活性。从机制上讲，我们的数据表明，OA 通过抑制 PI3K/Akt 通路在体外对 PC-3 和 DU145 细胞发挥抗癌作用。与此一致的是，OA 还通过抑制 PI3K/Akt 通路来抑制体内 PC-3 细胞的肿瘤生长。总之，我们的研究结果证明了 OA 在体外和体内前列腺癌细胞中的抗癌特性，并为 OA 作为前列腺癌患者的佐剂提供了实验证据。
Oleanolic acid (OA) is a naturally occurring pentacyclic triterpenoid and possesses diverse pharmacological activities, including anti-cancer effects that have been confirmed in multiple types of human cancers. However, the potential effect of natural OA on human prostate cancer is still unclear. The present study aimed to explore whether and how OA exerted anti-cancer effects in prostate cancer. Our data showed that OA inhibited cell viability and proliferation, and promoted cell apoptosis and G(0)/G(1) phase cell cycle arrest in prostate cancer PC-3, DU145, and LNCaP cells, in a dose-dependent manner. In addition, OA was found to regulate the expression levels of apoptosis-related and cell cycle-related proteins, as well as the activity of PI3K/Akt pathway, in a dose-dependent manner. Mechanistically, our data revealed that OA exerted anti-cancer effects in vitro in PC-3 and DU145 cells by repressing the PI3K/Akt pathway. In agreement, OA also suppressed the tumor growth of PC-3 cells in vivo via inhibition of the PI3K/Akt pathway. In conclusion, our findings demonstrate the anti-cancer properties of OA in prostate cancer cells, both in vitro and in vivo, and provide the experimental evidence for the use of OA as an adjuvant agent for prostate cancer patients.